Date: 2014-02-04
Type of information:
phase:
Announcement: presentation of results at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, USA (January 30 - February 1, 2014)
Company: MDxHealth (Belgium)
Product: ConfirmMDx® for Prostate Cancer
Action mechanism:
Disease: aggressive prostate cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest news: * On February 3, 2014, MDxHealth, a Belgian molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, has announced positive results from an important study designed to identify patients with aggressive prostate cancer. The study, presented at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, USA (January 30 - February 1, 2014), confirmed that epigenetic profiling of selected genes provides prognostic information, corresponding to Gleason score (GS), that could help to identify patients with aggressive PCa. In this study, the prognostic value of the epigenetic status of five genes (GSTP1, APC, RASSF1, RARB and LGALS3) in 84 prostatectomy samples with different GS\'s was evaluated. The results of a hierarchical clustering analysis showed that low gene methylation levels were detected in the vast majority of patient samples with GS6 and GS7 (3+4) PCa. In contrast, respectively 81% and 91% of the GS7 (4+3) and GS superior or egual 8 samples fell into the category with intermediate to high methylation levels. These data provide evidence of the potential prognostic value of epigenetically profiling selected genes to identify men with a low versus high risk for aggressive PCa. \"These important study results support our overall strategy of leveraging epigenetics to improve the diagnosis and treatment of prostate cancer patients. We were pleased to see that the data generated with the ConfirmMDx for Prostate Cancer genes, suggest the potential for prognostic utility,\" explained Dr. Jan Groen, CEO of MDxHealth. \"With this information, we are in a position to explore expansion of the ConfirmMDx indication for use in men diagnosed with GS6 prostate cancer, which may help urologists make more informed treatment decisions.\"
